Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer

Andre Konski, Deborah Watkins-Bruner, Steven Feigenberg, Alexandra Hanlon, Sachin Kulkarni, J. Robert Beck, Eric M. Horwitz, Alan Pollack

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background: The specific aim of this study is to evaluate the cost-effectiveness of intensity-modulated radiation therapy (IMRT) compared with three-dimensional conformal radiation therapy (3D-CRT) in the treatment of a 70-year-old with intermediate-risk prostate cancer. Methods: A Markov model was designed with the following states; posttreatment, hormone therapy, chemotherapy, and death. Transition probabilities from one state to another were calculated from rates derived from the literature for IMRT and 3D-CRT. Utility values for each health state were obtained from preliminary studies of preferences conducted at Fox Chase Cancer Center. The analysis took a payer's perspective. Expected mean costs, cost-effectiveness scatterplots, and cost acceptability curves were calculated with commercially available software. Results: The expected mean cost of patients undergoing IMRT was $47,931 with a survival of 6.27 quality-adjusted life years (QALYs). The expected mean cost of patients having 3D-CRT was $21,865 with a survival of 5.62 QALYs. The incremental cost-effectiveness comparing IMRT with CRT was $40,101/QALYs. Cost-effectiveness acceptability curve analysis revealed a 55.1% probability of IMRT being cost-effective at a $50,000/QALY willingness to pay. Conclusion: Intensity-modulated radiation therapy was found to be cost-effective, however, at the upper limits of acceptability. The results, however, are dependent on the assumptions of improved biochemical disease-free survival with fewer patients undergoing subsequent salvage therapy and improved quality of life after the treatment. In the absence of prospective randomized trials, decision analysis can help inform physicians and health policy experts on the cost-effectiveness of emerging technologies.

Original languageEnglish
Pages (from-to)408-415
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume66
Issue number2
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

cost effectiveness
Decision Support Techniques
Cost-Benefit Analysis
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
Quality-Adjusted Life Years
costs
Costs and Cost Analysis
acceptability
Therapeutics
health
therapy
Salvage Therapy
physicians
Survival
hormones
curves
chemotherapy

Keywords

  • Cost-effectiveness
  • Intensity-modulated radiation therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. / Konski, Andre; Watkins-Bruner, Deborah; Feigenberg, Steven; Hanlon, Alexandra; Kulkarni, Sachin; Beck, J. Robert; Horwitz, Eric M.; Pollack, Alan.

In: International Journal of Radiation Oncology Biology Physics, Vol. 66, No. 2, 01.10.2006, p. 408-415.

Research output: Contribution to journalArticle

Konski, Andre ; Watkins-Bruner, Deborah ; Feigenberg, Steven ; Hanlon, Alexandra ; Kulkarni, Sachin ; Beck, J. Robert ; Horwitz, Eric M. ; Pollack, Alan. / Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. In: International Journal of Radiation Oncology Biology Physics. 2006 ; Vol. 66, No. 2. pp. 408-415.
@article{cebf977dacde467fa39a033a5111ca73,
title = "Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer",
abstract = "Background: The specific aim of this study is to evaluate the cost-effectiveness of intensity-modulated radiation therapy (IMRT) compared with three-dimensional conformal radiation therapy (3D-CRT) in the treatment of a 70-year-old with intermediate-risk prostate cancer. Methods: A Markov model was designed with the following states; posttreatment, hormone therapy, chemotherapy, and death. Transition probabilities from one state to another were calculated from rates derived from the literature for IMRT and 3D-CRT. Utility values for each health state were obtained from preliminary studies of preferences conducted at Fox Chase Cancer Center. The analysis took a payer's perspective. Expected mean costs, cost-effectiveness scatterplots, and cost acceptability curves were calculated with commercially available software. Results: The expected mean cost of patients undergoing IMRT was $47,931 with a survival of 6.27 quality-adjusted life years (QALYs). The expected mean cost of patients having 3D-CRT was $21,865 with a survival of 5.62 QALYs. The incremental cost-effectiveness comparing IMRT with CRT was $40,101/QALYs. Cost-effectiveness acceptability curve analysis revealed a 55.1{\%} probability of IMRT being cost-effective at a $50,000/QALY willingness to pay. Conclusion: Intensity-modulated radiation therapy was found to be cost-effective, however, at the upper limits of acceptability. The results, however, are dependent on the assumptions of improved biochemical disease-free survival with fewer patients undergoing subsequent salvage therapy and improved quality of life after the treatment. In the absence of prospective randomized trials, decision analysis can help inform physicians and health policy experts on the cost-effectiveness of emerging technologies.",
keywords = "Cost-effectiveness, Intensity-modulated radiation therapy, Prostate cancer",
author = "Andre Konski and Deborah Watkins-Bruner and Steven Feigenberg and Alexandra Hanlon and Sachin Kulkarni and Beck, {J. Robert} and Horwitz, {Eric M.} and Alan Pollack",
year = "2006",
month = "10",
day = "1",
doi = "10.1016/j.ijrobp.2006.04.049",
language = "English",
volume = "66",
pages = "408--415",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer

AU - Konski, Andre

AU - Watkins-Bruner, Deborah

AU - Feigenberg, Steven

AU - Hanlon, Alexandra

AU - Kulkarni, Sachin

AU - Beck, J. Robert

AU - Horwitz, Eric M.

AU - Pollack, Alan

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Background: The specific aim of this study is to evaluate the cost-effectiveness of intensity-modulated radiation therapy (IMRT) compared with three-dimensional conformal radiation therapy (3D-CRT) in the treatment of a 70-year-old with intermediate-risk prostate cancer. Methods: A Markov model was designed with the following states; posttreatment, hormone therapy, chemotherapy, and death. Transition probabilities from one state to another were calculated from rates derived from the literature for IMRT and 3D-CRT. Utility values for each health state were obtained from preliminary studies of preferences conducted at Fox Chase Cancer Center. The analysis took a payer's perspective. Expected mean costs, cost-effectiveness scatterplots, and cost acceptability curves were calculated with commercially available software. Results: The expected mean cost of patients undergoing IMRT was $47,931 with a survival of 6.27 quality-adjusted life years (QALYs). The expected mean cost of patients having 3D-CRT was $21,865 with a survival of 5.62 QALYs. The incremental cost-effectiveness comparing IMRT with CRT was $40,101/QALYs. Cost-effectiveness acceptability curve analysis revealed a 55.1% probability of IMRT being cost-effective at a $50,000/QALY willingness to pay. Conclusion: Intensity-modulated radiation therapy was found to be cost-effective, however, at the upper limits of acceptability. The results, however, are dependent on the assumptions of improved biochemical disease-free survival with fewer patients undergoing subsequent salvage therapy and improved quality of life after the treatment. In the absence of prospective randomized trials, decision analysis can help inform physicians and health policy experts on the cost-effectiveness of emerging technologies.

AB - Background: The specific aim of this study is to evaluate the cost-effectiveness of intensity-modulated radiation therapy (IMRT) compared with three-dimensional conformal radiation therapy (3D-CRT) in the treatment of a 70-year-old with intermediate-risk prostate cancer. Methods: A Markov model was designed with the following states; posttreatment, hormone therapy, chemotherapy, and death. Transition probabilities from one state to another were calculated from rates derived from the literature for IMRT and 3D-CRT. Utility values for each health state were obtained from preliminary studies of preferences conducted at Fox Chase Cancer Center. The analysis took a payer's perspective. Expected mean costs, cost-effectiveness scatterplots, and cost acceptability curves were calculated with commercially available software. Results: The expected mean cost of patients undergoing IMRT was $47,931 with a survival of 6.27 quality-adjusted life years (QALYs). The expected mean cost of patients having 3D-CRT was $21,865 with a survival of 5.62 QALYs. The incremental cost-effectiveness comparing IMRT with CRT was $40,101/QALYs. Cost-effectiveness acceptability curve analysis revealed a 55.1% probability of IMRT being cost-effective at a $50,000/QALY willingness to pay. Conclusion: Intensity-modulated radiation therapy was found to be cost-effective, however, at the upper limits of acceptability. The results, however, are dependent on the assumptions of improved biochemical disease-free survival with fewer patients undergoing subsequent salvage therapy and improved quality of life after the treatment. In the absence of prospective randomized trials, decision analysis can help inform physicians and health policy experts on the cost-effectiveness of emerging technologies.

KW - Cost-effectiveness

KW - Intensity-modulated radiation therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=33748305706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748305706&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2006.04.049

DO - 10.1016/j.ijrobp.2006.04.049

M3 - Article

VL - 66

SP - 408

EP - 415

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -